MUC-1 expression in pleomorphic adenomas using two human milk fat globule protein membrane antibodies (HMFG-1 and HMFG-2)

Pleomorphic adenoma (PA) is the most common salivary gland tumor and its microscopic features and histogenesis are a matter of debate. Human milk fat globule protein membrane (HMFG) monoclonal antibodies (MoAbs) comprise a set of antibodies against the mucin 1 (MUC-1) protein detected in several salivary gland tumors. Objective The aim of this study was to assess the immunoexpression of the PA neoplastic cells to MUC-1 protein using HMFG-1 and HMFG-2 MoAbs, contrasting these results with those from normal salivary gland tissue. Material and Methods Immunohistochemical detection of MUC-1 protein using HMFG-1 and HMFG-2 MoAbs was made in 5 mm thick, paraffin embedded slides, and the avidin-biotin method was used. Results Positivity to HMFG-1 and HMFG-2 MoAbs was found in ductal, squamous metaplastic and neoplastic myoepithelial cells, keratin pearls and intraductal mucous material. Two kinds of myoepithelial cells were identified: classic myoepithelial cells around ducts were negative to both MoAbs, and modified myoepithelial cells were positive to both MoAbs. This last cellular group of the analyzed tumors showed similar MUC-1 immunoexpression to ductal epithelial cells using both HMFG antibodies. Intraductal mucous secretion was also HMFG-1 and HMFG-2 positive. Conclusions Our results showed there are two kinds of myoepithelial cells in PA. The first cellular group is represented by the different kinds of neoplastic myoepithelial cells and is HMFG-positive. The second one is HMFG-negative and represented by the neoplastic myoepithelial cells located around the ducts. .

Diagnostic and differential value of elevated serum KL-6 levels in pancreatic cancer / 中华胰腺病杂志

Objective To determine the serum KL-6 level in patients with pancreatic carcinoma and investigate its diagnostic value. Methods The data of 53 pancreatic carcinoma (PC) patients; 68 chronic pancreatitis (CP) patients and 51 patients with high risks of pancreatic cancer (HR) with complete follow-up data were studied, and 50 healthy volunteers were used as controls. ELISA was used to measure the serum levels of KL-6, MUC4, and CA50. Radioimmunoassay methods were used to measure the serum CA19-9 levels. The sensitivity and specificity of KL-6 for the diagnosis of PC were determined, and the relationship between its levels and clinicopathologic parameters, patients' outcome were analyzed. Results The serum KL-6 levels were (753±548), (135±93), (105±55) and (99±50) U/ml in PC group, CP group, HR group and control group, and the value in PC group was significantly higher than those in other 3 groups (P 232 U/ml as the cut-off point, the sensitivity and specificity of KL-6 for the diagnosis of PC was 96% and 94%. Using >244 U/ml as the cut-off point, the sensitivity and specificity of KL-6 for the diagnosis of PC was 97% and 91%. The clinical value of KL-6 was higher than those of CA19-9, CASO and MUC4. The serum level of KL-6 was not associated with clinicopathologic parameters. The median survival of patients with serum level of KL-6 =300 U/ml was (9.3 ±1.2) months, which was significantly longer than that in patients with serum level of KL-6 >300 U/ml [ (4.6 ±0.7) months, P =0.006]. Conclusions KL-6 might be a useful serological marker of pancreatic cancer, and it may play a role in the differential diagnosis between pancreatic cancer and chronic pancreatitis.

Expression of protein MUC1 and MUC2 in intraductal papillary mucinous neoplasms and its significance / 第二军医大学学报

Objective: To investigate the expression of protein MUC1 and MUC2 in intraductal papillary mucinous neoplasms (IPMNs) and its significance. Methods: Immunohistochemical method (En Vision) was used to analyze the expression of protein MUC1 and MUC2 in 18 IPMNs and 9 pancreatic ductal adenocarcinomas. Results: Expression of protein MUC1 was detected in 4 of the 18 (22%) IPMNs (including 1 with pancreatic intraductal papillary-mucinous carcinoma) and all the 9 (100%) the pancreatic ductal adenocarcinomas, with the latter significantly higher than the former(P<0.01). Expression of protein MUC2 was detected in 17 of the 18 (94.4%) IPMNs and in 1 of the 9 (11.1%) pancreatic ductal adenocarcinomas, with the former significantly higher than the latter(P< 0.01). The expression levels of MUC2 were significantly different in IPMNs of different types (IPMA, IPMB, and IPMC, P<0.05). Conclusion: IPMNs have high expression of MUC2 and the expression is associated with the pathological types of IPMN. MUC1 expression may serve as a marker of malignant IPMNs and is worth further studying.

Construction and identification of eukaryotic expressing vector for multiple myeloma MUC1-2VNTR / 白血病·淋巴瘤

Objective To construct multiple myeloma mucin MUC1-2VNTR gene eukaryotic expressing vector,which provided the basic material for further study of multiple myeloma DNA vaccine.Methods MUC1-2VNTR coding gene as target gene,and a KOZAK sequence was inserted before it.Hind Ⅲ and Xba Ⅰ restriction enzyme site were inserted on both ends.Then the whole sequence was synthesized and cloned into pcDNA3.1/myc-his B vector,and the recombinant vector was identified by restriction enzyme digestion and DNA sequencing.Results Synthesized MUC1-2VNTR gene was 140 bp.Restriction enzyme digestion and DNA sequencing confirmed pcDNA3.1/MUC1-2VNTR/myc-his B including the whole exact translation frame region and MUC1-2VNTR gene.Condnsion The pcDNA3.1/MUC1-2VNTR/myc-his B has been successfully constructed,which provides the basic material for further studies of MUC1 mucin function and multiple myloma DNA vaccine.

Cellular localization of MUC1 in Benign and Malignant Breast Lesions with the Histological Correlation and the Prognostic Significance / 한국유방암학회지

PURPOSE: MUC1 is a large transmembrane glycoprotein, which is overexpressed in the majority of carcinomas. The high expression of MUC1 is associated with aggressive tumors, with the MUC1 antigen used as a marker to monitor disease progression in breast cancer patients. Although the MUC1 tumor marker is both sensitive and specific for predicting a relapse in breast cancer, it is not commonly used during the follow-up of breast cancer patients. The aim of this study was to evaluate whether the differential patterns of MUC1 expression in different histological types of breast carcinoma could be used to distinguish tumors from benign lesions, and determine its prognostic relevance with other biological parameters. METHODS: 22 normal breast, 7 intraductal hyper-plasia (IDH) and 307 malignant lesions were selected and immunostained with MUC1. The patterns of reaction were classified as intraluminal border (ILB), cytoplasmic, intercellular membrane (ICM), intranuclear or mixed staining. RESULTS: All the normal breast samples showed weak cytoplasmic staining in the ducts and lobules. All the IDH samples showed moderate cytoplasmic and ILB staining. Of the 307 malignant lesions, only 2 (0.8%) showed negative staining; MUC1 positivity was observed in 4 (1.3%), with only ILB staining; 8 (2.6%) with weak cytoplasmic staining, 16 (5.2%) with weak cytoplasmic and intranuclear staining, 168 (54.7%) with moderate cytoplasmic and ILB staining, and 109 (35.5%) with strong cytoplasmic and ICM staining. MUC1 positivity with a moderate to strong staining intensity was observed in 90.6% of the infiltrating ductal carcinomas (221/244), 96.5% of the intraductal carcinomas (28/29), 87.5% of the infiltrating lobular carcinomas (7/8), 66.6% of the mucinous and secretory carcinomas (10/15), 100.0% of the apocrine carcinomas (5/5) and 100.0% of the medullary carcinomas (6/6). The expression of MUC1 was statistically significant between the histological tumor types (p = 0.034), tumor size (p = 0.046), and HER-2/neu (p = 0.004). CONCLUSION: These data suggest the expression of MUC1 was different in normal breast, IDH and malignant breast tumors, and was significantly correlated with the histological tumor types, tumor size and HER-2/neu oncogene.